SIGA Technologies

Today we announced an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) with potential applications in a broad range of orthopoxviruses. Learn more in our press release: https://lnkd.in/ecd3xHyJ

Last week, our VP and Head of International Markets, Victor Gomes, MBA, had the privilege of attending the Health Emergency Preparedness and Response Authority (HERA) #InfoDay in Budapest.   As we develop medicines to prevent and treat emerging #infectiousdiseases with high unmet medical needs, it was a pleasure to connect with global health leaders to exchange insights and discuss opportunities for collaboration between private sector, member states and health authorities for enhancing #healthsecurity. Thank you to EU in Emergencies and the European Commission for facilitating these important discussions!

Today we announced that we entered an agreement to supply our antiviral therapy in Morocco in response to a request from the Ministry of Health to help prepare and protect its citizens. We are proud to reaffirm our commitment to global #healthsecurity. See the full press release: https://lnkd.in/e9Wtrz6x

The escalating #mpox outbreak is raising alarms about a potential multi-country epidemic or even a new pandemic. This year alone, over 17,000 suspected cases have been reported across Africa, predominantly in the Democratic Republic of the Congo, underscoring the critical importance of a unified global response to combat the spread. In this JAMA publication, senior scholars from Johns Hopkins Center for Health Security examine the current global governance framework for a public health emergency of international concern (PHEIC), assess the mpox outbreak in Africa, and underscore the urgent need for countries to take swift action in response to this international call. See here: https://lnkd.in/enzvjjtf @Caitlin Rivers @Crystal Watson @Alexandra Phelan

Since the World Health Organization declared #mpox a public health emergency of international concern (#PHEIC) last month, two people traveling to Africa – one from Sweden and one from Thailand – have become infected with the clade Ib virus and brought it back to their home countries. As mpox spreads rapidly, Nature spoke with #infectiousdisease specialists to explore how this current emergency compares to the global outbreak of 2022 and how the clade Ib strain differs from the clade II strain that caused the earlier outbreak. Stay informed about the mpox outbreak and its impact on #publichealth: https://lnkd.in/gh4uM8jV

In light of the World Health Organization's recent declaration of #mpox as a public health emergency of international concern (#PHEIC), it is essential to understand what mpox is and how it affects individuals. Mpox is a viral illness caused by the monkeypox virus and is categorized into two distinct clades: clade I, and clade II. Mpox remains a significant threat, with recent surges in cases—particularly from clades Ia and Ib—in the Democratic Republic of the Congo and other affected regions raising considerable concern. As we work together to mitigate the impact of mpox, staying informed about the virus is key to effective prevention and treatment. Learn more on WHO’s website: https://lnkd.in/drvpM43B #MpoxAwareness

Faced once again with the rapidly spreading epidemic of #mpox, the World Health Organization declared a #publichealth emergency of international concern (#PHEIC). WHO’s declaration was prompted by an escalating crisis of mpox concentrated in the Democratic Republic of the Congo and experts warn that if the outbreak is not contained, the virus could potentially spread globally. Featuring insights from our Executive Vice President and Chief Medical Officer, Dr. Jay K. Varma, this The New York Times article provides a comprehensive analysis of the current mpox crisis and delves into the challenges of managing the outbreak, the status of available treatments, and the critical importance of a coordinated global response. Read the full article here: https://lnkd.in/e4vRnVbV

Following the declaration of a #publichealth emergency of international concern, the World Health Organization launched a global Strategic Preparedness and Response Plan to stop outbreaks of human-to-human transmission of #mpox through coordinated global, regional, and national efforts. As we develop medicines to potentially prevent and treat emerging #infectiousdiseases such as mpox, we are proud to be part of the collective effort to mitigate the impact of the disease.   The WHO R&D Blueprint, along with the Africa CDC, CEPI (Coalition for Epidemic Preparedness Innovations) and National Institute of Allergy and Infectious Diseases (NIAID), will host a virtual scientific conference this week to align mpox research with outbreak control goals. Learn more about WHO’s plan and upcoming conference: https://lnkd.in/g7jJEDJ9

The #COVID19 pandemic highlighted the need to upgrade systems for #infectiousdisease surveillance, forecasting, and modeling. These systems are crucial for shaping evidence-based #publichealth guidance and policies. Dr. Jay K. Varma, our Executive Vice President and Chief Medical Officer, co-authored a publication in the Frontiers of Public Health, delving into the essential components of an effective surveillance system. This publication draws upon the lessons learned from COVID-19 in the U.S. while also examining international jurisdictions to gain insights on the importance of specific data types. See here: https://lnkd.in/eS_AArfe